Result of AGM

RUA Life Sciences PLC

23 August 2023

 

23 August 2023

RUA Life Sciences plc

("RUA" the "Company" or the "Group")

Result of AGM

RUA Life Sciences plc (AIM:RUA.L), the holding company of a group of medical device businesses focussed on the exploitation of the world's leading long-term implantable biostable polymer (Elast-Eon ™), announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:

Res No.	Votes For	%	Votes Against	%	Votes Total	% I.S.C.	Votes Withheld
1	3,120,357	100.00%	0	0.00%	3,120,357	14.07	0
2	2,229,757	71.48%	889,792	28.52%	3,119,549	14.06	808
3	2,955,917	95.24%	147,790	4.76%	3,103,707	13.99	16,650
4	2,951,476	95.23%	147,790	4.77%	3,099,266	13.97	21,091
5	3,093,484	99.67%	10,223	0.33%	3,103,707	13.99	16,650
6	2,980,778	95.53%	139,356	4.47%	3,120,134	14.06	223
7	2,980,448	95.53%	139,569	4.47%	3,120,017	14.06	340
8	2,951,597	95.48%	139,569	4.52%	3,091,166	13.93	29,191

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.rualifesciences.com).

QCA Code - statement regarding voting result

The board notes that although Resolution 2 (remuneration committee report) passed with the requisite majority, it received more than 20% of votes against the board's recommendation. We thank shareholders for their support and the Board will look to continue engagement throughout the year. The board encourages an open and constructive dialogue directly with shareholders and continue to be willing to engage with any shareholder on any relevant topics should they so wish.

For further information contact:

RUA Life Sciences

Bill Brown, Chairman                                                                Tel: [phone]  

Dr Caroline Stretton, Group MD                                             Tel: [phone]

Cenkos Securities plc (Nominated Adviser and Broker)   Tel: [phone]

Giles Balleny / Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

END